Qube Research & Technologies Ltd - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 384 filers reported holding HALOZYME THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.1%.

Quarter-by-quarter ownership
Qube Research & Technologies Ltd ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$984,834
-80.3%
25,781
-81.4%
0.00%
-83.3%
Q2 2023$4,990,465
+586.2%
138,355
+626.5%
0.02%
+500.0%
Q1 2023$727,290
-87.8%
19,044
-81.8%
0.00%
-90.6%
Q4 2022$5,958,340
+154.0%
104,716
+96.4%
0.03%
+88.2%
Q2 2022$2,346,000
+468.0%
53,329
+425.3%
0.02%
+240.0%
Q3 2021$413,000
-58.2%
10,153
-53.3%
0.01%
-54.5%
Q2 2021$987,000
-52.7%
21,732
-56.6%
0.01%
-66.7%
Q1 2021$2,087,000
-20.5%
50,054
-18.6%
0.03%
-10.8%
Q4 2020$2,626,000
+713.0%
61,492
+401.0%
0.04%
+640.0%
Q3 2020$323,000
-29.6%
12,273
-28.3%
0.01%
-28.6%
Q2 2020$459,000
-65.0%
17,111
-76.8%
0.01%
-82.9%
Q4 2019$1,310,00073,8970.04%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q1 2023
NameSharesValueWeighting ↓
Third Security, LLC 19,816,162$191,226,0008.73%
BB BIOTECH AG 6,825,532$65,866,0002.13%
Lombard Odier Asset Management (USA) Corp 2,700,000$26,055,0001.79%
SECTORAL ASSET MANAGEMENT INC 3,724,351$35,940,0001.61%
QVT Financial LP 2,010,186$19,398,0000.97%
JHL Capital Group LLC 1,475,000$14,234,0000.94%
MAZAMA CAPITAL MANAGEMENT INC 358,087$3,456,0000.79%
EcoR1 Capital, LLC 160,700$1,551,0000.78%
Alden Global Capital Ltd 332,500$3,209,0000.77%
IRIDIAN ASSET MANAGEMENT LLC/CT 7,274,065$70,195,0000.65%
View complete list of HALOZYME THERAPEUTICS INC shareholders